MCID: SKL003
MIFTS: 41

Skeletal Muscle Cancer

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Skeletal Muscle Cancer

MalaCards integrated aliases for Skeletal Muscle Cancer:

Name: Skeletal Muscle Cancer 12 14
Skeletal Muscle Neoplasm 12 14 69
Malignant Tumor of Skeletal Muscle 12
Tumor of Skeletal Muscle 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4043 DOID:4044
NCIt 47 C6516 C6514
SNOMED-CT 64 699955004

Summaries for Skeletal Muscle Cancer

MalaCards based summary : Skeletal Muscle Cancer, also known as skeletal muscle neoplasm, is related to rhabdomyosarcoma and spleen cancer. An important gene associated with Skeletal Muscle Cancer is MYOD1 (Myogenic Differentiation 1), and among its related pathways/superpathways are Developmental Biology and MAPK Signaling: Mitogen Stimulation Pathway. The drugs Pioglitazone and 2,4-thiazolidinedione have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, lung and bone, and related phenotypes are growth/size/body region and cellular

Related Diseases for Skeletal Muscle Cancer

Diseases related to Skeletal Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
id Related Disease Score Top Affiliating Genes
1 rhabdomyosarcoma 10.7
2 spleen cancer 10.6 MB MYOD1
3 cowper gland carcinoma 10.6 IGF2 MB
4 phagocyte bactericidal dysfunction 10.5 MB MYOG
5 transitional cell carcinoma 10.5 MB MYOD1
6 phosphoserine aminotransferase deficiency 10.5 MYF6 MYOD1
7 bile duct sarcoma 10.5 MB MYOD1 MYOG
8 spindle cell sarcoma 10.4 CDK4 MB MYOD1
9 lateral medullary syndrome 10.4 MB MYOD1 MYOG
10 embryonal extrahepatic bile duct rhabdomyosarcoma 10.4 MB MYOD1 PAX3 PAX7
11 pineal parenchymal tumor of intermediate differentiation 10.4 MYF6 MYOD1 PAX3 PAX7
12 mucinous ovarian cystadenoma 10.4 MB MYOD1
13 melanotic medulloblastoma 10.4 MB MYOD1 MYOG
14 testis rhabdomyosarcoma 10.4 MYOD1 MYOG
15 cerebrum cancer 10.4 IGF1R IGF2 MB MYOD1
16 primary pulmonary lymphoma 10.4 CDK4 MYOD1 MYOG
17 cutaneous liposarcoma 10.3 CDK4 MYOD1 MYOG
18 enamel hypoplasia cataract hydrocephaly 10.3 CDK4 MYOD1 MYOG
19 neurodegeneration with brain iron accumulation 10.2 IGF2 MEF2A MEF2C MYOD1
20 3-hydroxyisobutryl-coa hydrolase deficiency 10.2 FOXO1 MEF2A MYOD1
21 hyperbiliverdinemia 10.1 IGF1R IGF2 MYOD1 MYOG
22 adenosarcoma 10.1 CDK4 IGF2 MB MYOG
23 lung clear cell-sugar-tumor 9.8 CDK4 CDKN1A MB MYOD1 MYOG
24 kala-azar 1 9.8 FOXO1 IGF1R IGF2 MYOG
25 granular cell leiomyosarcoma 9.8 MYF5 MYF6 MYOD1 MYOG PAX7
26 colon leiomyosarcoma 9.8 MYF5 MYF6 MYOD1 MYOG PAX7
27 46xy sex reversal 5 9.8 MB MYF6 MYOD1 TFE3
28 muscle cancer 9.8
29 multilocular clear cell renal cell carcinoma 9.7 FOXO1 PAX3 TFE3
30 pulmonary immaturity 9.7 KIDINS220 MYF5 MYF6 MYOD1 MYOG
31 breast cancer 9.6
32 cervicitis 9.6
33 prostate embryonal rhabdomyosarcoma 9.6 CDK4 IGF2 MB MYOD1 MYOG PAX3
34 ischemia 9.4 FOXO1 MB MYF5 MYOD1 MYOG PAX3
35 tyrosinemia 9.1 MYF5 PAX3 TFE3
36 rhabdomyosarcoma 2, alveolar 8.6 CDK4 FOXO1 IGF1R KIDINS220 MB MYOD1
37 prostate rhabdomyosarcoma 8.2 CDK4 FOXO1 IGF1R IGF2 MB MYF5
38 mediastinum rhabdomyosarcoma 8.1 FOXO1 IGF2 KIDINS220 MB MYOD1 MYOG
39 central nervous system rhabdomyosarcoma 4.6 CDK4 CDKN1A FOXO1 IGF1R IGF2 JDP2

Graphical network of the top 20 diseases related to Skeletal Muscle Cancer:



Diseases related to Skeletal Muscle Cancer

Symptoms & Phenotypes for Skeletal Muscle Cancer

MGI Mouse Phenotypes related to Skeletal Muscle Cancer:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.49 CDK4 CDKN1A FOXO1 IGF1R IGF2 KIDINS220
2 cellular MP:0005384 10.45 CDK4 CDKN1A FOXO1 IGF1R IGF2 JDP2
3 cardiovascular system MP:0005385 10.4 MB MEF2A MEF2C MYOD1 NACA PAX3
4 homeostasis/metabolism MP:0005376 10.39 IGF1R IGF2 JDP2 MB MYF5 MYF6
5 mortality/aging MP:0010768 10.39 CDK4 CDKN1A FOXO1 IGF1R IGF2 KIDINS220
6 behavior/neurological MP:0005386 10.37 CDK4 CDKN1A FOXO1 IGF1R IGF2 MEF2A
7 embryo MP:0005380 10.36 CDK4 CDKN1A FOXO1 IGF1R IGF2 MB
8 muscle MP:0005369 10.31 PAX3 PAX7 TFAP2B CDK4 CDKN1A FOXO1
9 hematopoietic system MP:0005397 10.3 PAX7 RHD TFE3 CDK4 CDKN1A FOXO1
10 immune system MP:0005387 10.24 IGF2 JDP2 MEF2C MYF5 PAX3 PAX7
11 craniofacial MP:0005382 10.22 CDKN1A FOXO1 IGF1R IGF2 MEF2C MYF5
12 adipose tissue MP:0005375 10.2 MYOG CDKN1A FOXO1 IGF1R JDP2 MYF5
13 integument MP:0010771 10.18 CDK4 CDKN1A FOXO1 IGF1R IGF2 JDP2
14 digestive/alimentary MP:0005381 10.1 CDK4 CDKN1A FOXO1 IGF1R IGF2 PAX3
15 normal MP:0002873 10.07 MYF6 MYOD1 MYOG NACA PAX3 PAX7
16 limbs/digits/tail MP:0005371 10.06 CDKN1A FOXO1 IGF1R IGF2 JDP2 MEF2C
17 neoplasm MP:0002006 10.02 CDK4 CDKN1A FOXO1 IGF1R MYF5 MYF6
18 no phenotypic analysis MP:0003012 10.02 CDKN1A FOXO1 IGF2 KIDINS220 MYF5 MYF6
19 respiratory system MP:0005388 9.97 MYOD1 MYOG PAX3 PAX7 TFAP2B CDKN1A
20 skeleton MP:0005390 9.8 MEF2C MYF5 MYF6 MYOD1 MYOG NACA
21 vision/eye MP:0005391 9.28 CDK4 CDKN1A IGF2 KIDINS220 MYF5 MYF6

Drugs & Therapeutics for Skeletal Muscle Cancer

Drugs for Skeletal Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
3 HIV Protease Inhibitors Phase 4
4 Hypoglycemic Agents Phase 4,Phase 1
5 insulin Phase 4
6 Insulin, Globin Zinc Phase 4
7 Matrix Metalloproteinase Inhibitors Phase 4
8
protease inhibitors Phase 4
9 TIMP1 protein, human Phase 4
10 TIMP3 protein, human Phase 4
11 Tissue Inhibitor of Metalloproteinase-1 Phase 4
12 Tissue Inhibitor of Metalloproteinase-3 Phase 4
13 Tissue Inhibitor of Metalloproteinases Phase 4
14 glutamine Nutraceutical Phase 4
15
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
16
Menthol Approved Phase 1, Phase 2 2216-51-5 16666
17
Methyltestosterone Approved Phase 2 58-18-4 6010
18
Testosterone Approved, Investigational Phase 2 58-22-0 6013
19
Calcitriol Approved, Nutraceutical Phase 2 32222-06-3 134070 5280453
20 Antidotes Phase 2
21 Anti-Infective Agents Phase 2,Phase 1
22 Antioxidants Phase 2
23 Antiviral Agents Phase 2
24 Expectorants Phase 2
25 N-monoacetylcystine Phase 2
26 Protective Agents Phase 2
27 Respiratory System Agents Phase 2
28 Bone Density Conservation Agents Phase 2
29 Calcium, Dietary Phase 2
30 Micronutrients Phase 2
31 Trace Elements Phase 2
32 Vasoconstrictor Agents Phase 2
33 Vitamins Phase 2
34 Hormone Antagonists Phase 2
35 Hormones Phase 2
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
37 Anabolic Agents Phase 2
38 Androgens Phase 2
39 Antineoplastic Agents, Hormonal Phase 2
40 Testosterone 17 beta-cypionate Phase 2
41
Testosterone enanthate Phase 2 315-37-7 9416
42 Testosterone undecanoate Phase 2
43 leucine Nutraceutical Phase 2
44 histidine Nutraceutical Phase 2
45
Metformin Approved Phase 1 657-24-9 14219 4091
46
Everolimus Approved Phase 1 159351-69-6 6442177
47
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
48
Nitric Oxide Approved Phase 1 10102-43-9 145068
49
Nitroprusside Approved Phase 1 15078-28-1 11963622
50
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 76)

id Name Status NCT ID Phase Drugs
1 Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes Completed NCT01223196 Phase 4 Pioglitazone;Placebo
2 The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies Active, not recruiting NCT01552291 Phase 4 Placebo
3 L-leucine in Diamond Blackfan Anemia Patients Unknown status NCT02386267 Phase 2 L-leucine
4 Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II Completed NCT01694602 Phase 2
5 Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training Completed NCT00196885 Phase 2 N-acetylcysteine
6 Feasibility of Home vs. Hospital Based Resistance Training for Advanced Cancer Patients Completed NCT02930876 Phase 2
7 Calcitriol, Physical Activity, and Bone Health in Cancer Survivors Completed NCT00904033 Phase 2 calcitriol
8 Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors Recruiting NCT02739620 Phase 1, Phase 2
9 Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer Recruiting NCT02433197 Phase 1, Phase 2
10 Study of Testosterone and Athlete Response Recruiting NCT03210558 Phase 2 Testosterone cream 1% (Andro-Feme® );Placebo cream
11 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1 Metformin
12 Nutritional and Contractile Regulation of Muscle Growth Completed NCT00891696 Phase 1 Rapamycin;Sodium nitroprusside
13 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients Terminated NCT00040651 Phase 1 Fludarabine;Cyclophosphamide;Thymoglobulin
14 Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer Withdrawn NCT02106871 Phase 1 Sildenafil
15 Role of Activin A (ActA) in the Human Cancer Cachexia Unknown status NCT01604642
16 Physiotherapy in Hematopoietic Stem Cell Transplantation Unknown status NCT02193399
17 Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis Unknown status NCT02287363
18 Effects of High Intensity Interval Training and Strength Training in Obese Unknown status NCT02484235
19 Rehabilitation in Pulmonary Sarcoidosis: a Prospective Study Unknown status NCT01384123
20 Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients Completed NCT00446888
21 Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients Completed NCT00994669
22 Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss Completed NCT00899158
23 Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients Completed NCT01015274
24 Assessment of in Vivo Skeletal Muscle Viscoelasticity (ARFI Imaging) With Aging and Cancer Completed NCT01484821
25 Feasibility of a Short Home-based Rehabilitation Program for Cancer Patients Waiting for Lung Resection Surgery Completed NCT01667237 Early Phase 1
26 Rehabilitation for Head and Neck Cancer Completed NCT02439892
27 Feasibility of Systematic Handgrip Strength (HGS) Testing and Short-term Changes in Muscle Strength in Digestive Cancer Patients Treated by Chemotherapy Completed NCT02797197 chemotherapy
28 Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients Completed NCT01136083
29 Improving Muscle for Functional Independence Trial Completed NCT01049698
30 Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States Completed NCT00461240
31 Fish Oil Supplement in Rectal Cancer Completed NCT02534389
32 Alterations of Muscle Secretome Associated With Muscle Atrophy Caused by Glucocorticoids Completed NCT03229395
33 Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia Completed NCT02116166
34 NAC Supplementation and Skeletal Muscle Performance Completed NCT01778309
35 Green Tea, High in Epigallocatechin Gallate (EGCG) and Postprandial Fat Oxidation Completed NCT00867555
36 Time Course and Nature of Nutrient Sensing During Fasting in Humans Completed NCT01387919
37 Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients Completed NCT02571088
38 Skeletal Muscle Atrophy and Dysfunction in Human Cancer Recruiting NCT02949076
39 Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer Recruiting NCT02573974
40 Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss Recruiting NCT03027479
41 Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology Recruiting NCT03012139
42 Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer Recruiting NCT02722525
43 Effects of WB-EMS and Specific Dietary Supplements on Cancer Patients Recruiting NCT03151291
44 EDICT - Exercise inDuced Changes In Colorectal Cancer Tissues Recruiting NCT02056691
45 The Role of Muscle Cachexia in Pancreatic Cancer Recruiting NCT02515513
46 Muscle Wasting in Cancer (MWIC) Recruiting NCT03191955
47 Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT) Recruiting NCT01998152
48 Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients Recruiting NCT02978521
49 Effects of WB-EMS and Dietetic Treatment on Cancer Patients Recruiting NCT02293239
50 Determining Energy Needs in Colorectal Cancer Recruiting NCT03131921

Search NIH Clinical Center for Skeletal Muscle Cancer

Genetic Tests for Skeletal Muscle Cancer

Anatomical Context for Skeletal Muscle Cancer

MalaCards organs/tissues related to Skeletal Muscle Cancer:

39
Skeletal Muscle, Lung, Bone, Heart, Prostate, Testes, Colon

Publications for Skeletal Muscle Cancer

Articles related to Skeletal Muscle Cancer:

id Title Authors Year
1
Cytotoxicity Studies of the Extracts, Fractions, and Isolated Compound of Pseudocedrela kotschyi on Cervical Cancer (HeLa), Breast Cancer (MCF-7) and Skeletal Muscle Cancer (RD) Cells. ( 28250653 )
2017
2
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. ( 20193046 )
2010

Variations for Skeletal Muscle Cancer

Expression for Skeletal Muscle Cancer

Search GEO for disease gene expression data for Skeletal Muscle Cancer.

Pathways for Skeletal Muscle Cancer

Pathways related to Skeletal Muscle Cancer according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 CDK4 FOXO1 MEF2A MEF2C MYF5 MYF6
2
Show member pathways
12.08 CDK4 CDKN1A FOXO1 IGF1R
3 12.06 CDKN1A FOXO1 IGF1R MEF2C PAX3 PAX7
4 11.85 CDKN1A FOXO1 MEF2A MEF2C
5 11.81 CDK4 CDKN1A FOXO1 IGF1R IGF2
6 11.78 MEF2C MYF5 MYOD1 MYOG PAX3 PAX7
7 11.74 PAX3 PAX7 TFAP2B
8 11.72 FOXO1 MEF2C MYOD1
9 11.59 CDKN1A MYF6 MYOD1
10 11.48 IGF1R IGF2 MEF2C
11 11.45 CDKN1A MEF2C MYOD1 PAX3
12
Show member pathways
11.37 CDKN1A IGF1R IGF2 MEF2A MEF2C MYF6
13 11.32 CDK4 CDKN1A FOXO1 MEF2C MYOD1 TFE3
14 11.24 CDKN1A FOXO1 MYOD1
15 11.21 MEF2A MEF2C MYOD1
16 11.11 MEF2A MEF2C MYF5 MYOD1 PAX7
17 10.65 MEF2A MEF2C

GO Terms for Skeletal Muscle Cancer

Cellular components related to Skeletal Muscle Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 CDK4 CDKN1A FOXO1 JDP2 MEF2A MEF2C
2 transcription factor complex GO:0005667 9.46 CDK4 MEF2A MYOD1 MYOG
3 nucleoplasm GO:0005654 9.4 CDK4 CDKN1A FOXO1 MEF2A MEF2C MYF5
4 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.26 CDK4 CDKN1A

Biological processes related to Skeletal Muscle Cancer according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.99 FOXO1 JDP2 MEF2A MEF2C TFAP2B
2 skeletal muscle cell differentiation GO:0035914 9.83 MEF2C MYF5 MYF6 MYOD1 MYOG
3 skeletal muscle tissue regeneration GO:0043403 9.81 MYF6 MYOG NACA PAX7
4 positive regulation of myoblast fusion GO:1901741 9.8 MYF5 MYF6 MYOD1 MYOG
5 ossification GO:0001503 9.79 IGF2 MYF5 MYOG
6 insulin receptor signaling pathway GO:0008286 9.77 FOXO1 IGF1R IGF2
7 myotube differentiation GO:0014902 9.74 MEF2C MYOD1 MYOG
8 muscle tissue morphogenesis GO:0060415 9.72 MYF5 MYF6 PAX7
9 positive regulation of skeletal muscle fiber development GO:0048743 9.67 MYF5 MYF6 MYOD1 MYOG
10 positive regulation of myoblast differentiation GO:0045663 9.65 MEF2C MYF5 MYF6 MYOD1 MYOG
11 skeletal muscle tissue development GO:0007519 9.63 MEF2C MYF5 MYF6 MYOD1 MYOG PAX7
12 response to hyperoxia GO:0055093 9.62 CDK4 CDKN1A
13 muscle cell fate commitment GO:0042693 9.62 MYF5 MYF6 MYOD1 MYOG
14 positive regulation of muscle cell differentiation GO:0051149 9.43 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
15 muscle organ development GO:0007517 9.23 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
16 transcription, DNA-templated GO:0006351 10.34 FOXO1 JDP2 MEF2A MEF2C MYF5 MYOD1
17 regulation of transcription, DNA-templated GO:0006355 10.32 FOXO1 IGF2 JDP2 MEF2A MEF2C MYF5
18 multicellular organism development GO:0007275 10.22 CDK4 IGF2 MEF2A MEF2C MYF5 MYF6
19 transcription from RNA polymerase II promoter GO:0006366 10.14 MEF2A MEF2C MYF5 MYF6 MYOD1 PAX3
20 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.14 FOXO1 MEF2A MEF2C MYF5 MYF6 MYOD1
21 cell differentiation GO:0030154 10.13 FOXO1 MEF2A MEF2C MYF5 MYF6 MYOD1
22 regulation of transcription from RNA polymerase II promoter GO:0006357 10.12 CDKN1A FOXO1 JDP2 MYF5 MYF6 MYOD1
23 positive regulation of transcription, DNA-templated GO:0045893 10.11 FOXO1 MEF2A MEF2C MYF6 MYOD1 MYOG
24 negative regulation of apoptotic process GO:0043066 10 CDKN1A FOXO1 IGF1R PAX7 TFAP2B

Molecular functions related to Skeletal Muscle Cancer according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.97 JDP2 MEF2A MEF2C MYF5 MYF6 MYOD1
2 sequence-specific DNA binding GO:0043565 9.97 FOXO1 MEF2A MEF2C MYF5 MYOD1 MYOG
3 chromatin binding GO:0003682 9.95 FOXO1 JDP2 MEF2A MEF2C MYOD1 TFAP2B
4 transcription factor activity, sequence-specific DNA binding GO:0003700 9.9 FOXO1 JDP2 MEF2A MEF2C MYF6 MYOD1
5 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.89 MEF2A MEF2C MYOG TFAP2B TFE3
6 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.86 JDP2 MEF2A MEF2C MYF5 MYF6 MYOD1
7 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.84 MEF2A MEF2C MYOD1 MYOG
8 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.83 FOXO1 MEF2A MEF2C TFAP2B
9 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0001228 9.81 MYF5 MYF6 MYOD1 MYOG
10 E-box binding GO:0070888 9.71 MYF5 MYF6 MYOD1 MYOG
11 transcription factor activity, RNA polymerase II core promoter sequence-specific GO:0000983 9.63 MEF2C PAX7 TFAP2B
12 HMG box domain binding GO:0071837 9.55 MEF2C PAX3
13 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.43 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
14 protein dimerization activity GO:0046983 9.23 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
15 DNA binding GO:0003677 10.21 FOXO1 JDP2 MEF2A MEF2C MYF5 MYF6

Sources for Skeletal Muscle Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....